Austin Aerts Sells 7,179 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 7,179 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $52,550.28. Following the completion of the transaction, the chief financial officer now directly owns 291,486 shares in the company, valued at approximately $2,133,677.52. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Austin Aerts also recently made the following trade(s):

• On Tuesday, September 10th, Austin Aerts sold 5,056 shares of Sera Prognostics stock. The shares were sold at an average price of $7.57, for a total value of $38,273.92.

Sera Prognostics Trading Down 2.7 %

Sera Prognostics stock traded down $0.20 during trading on Tuesday, hitting $7.24. 79,534 shares of the company were exchanged, compared to its average volume of 175,932. The business’s 50 day moving average is $7.41 and its 200 day moving average is $7.68. Sera Prognostics, Inc. has a 52 week low of $1.65 and a 52 week high of $12.35. The company has a market capitalization of $241.59 million, a P/E ratio of -7.31 and a beta of 1.04.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same quarter last year, the firm posted ($0.23) EPS. Equities analysts expect that Sera Prognostics, Inc. will post -0.95 EPS for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors have recently added to or reduced their stakes in the stock. Quest Partners LLC lifted its position in shares of Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after purchasing an additional 5,415 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Sera Prognostics in the third quarter valued at approximately $78,000. The Manufacturers Life Insurance Company purchased a new stake in Sera Prognostics in the second quarter valued at approximately $68,000. Prime Capital Investment Advisors LLC purchased a new stake in Sera Prognostics in the third quarter valued at approximately $104,000. Finally, Lake Street Advisors Group LLC acquired a new position in Sera Prognostics in the second quarter valued at approximately $144,000. 54.64% of the stock is owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.